Vimarsana
Biggest News Aggregation in the World

Page 34 - John Leonard News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Leonard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Leonard Today - Breaking & Trending Today

Intellia Therapeutics Gets Phase III Greenlight from FDA for Gene Editing Therapy - Vimarsana News

Intellia Therapeutics Gets Phase III Greenlight from FDA for Gene Editing Therapy

The trial, which is the first late-stage study of an in vivo CRISPR treatment in the U.S., will start by the end of 2023. Intellia's NTLA-2001 is a treatment candidate for transthyretin amyloidosis cardiomyopathy.

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - Vimarsana News

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

NTLA-2001 is the first-ever investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development CAMBRIDGE, Mass., Oct. 18, 2023 -- Intellia...

[Event] 12th Advanced Forum on Import Compliance & Enforcement - November 7th - 8th, Washington, DC | American Conference Institute (ACI) - Vimarsana News

[Event] 12th Advanced Forum on Import Compliance & Enforcement - November 7th - 8th, Washington, DC | American Conference Institute (ACI)

Back by popular demand! Join U.S. imports/customs controls experts and supply chain professionals at ACI’s Advanced Forum on Import Compliance and Enforcement, taking place November...

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema - Vimarsana News

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Oct. 13, 2023 -- Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based...

A decade later, biotech's CRISPR revolution is still going strong - Vimarsana News

A decade later, biotech's CRISPR revolution is still going strong

BioPharma